Antihypertensive Medication Use and Incident Breast Cancer in Women

Elizabeth E. Devore, ScD<sup>1</sup>, Sung Kim<sup>2</sup>, Cody A. Ramin, ScM<sup>1,3</sup>, Lani R. Wegrzyn, MS<sup>4</sup>, Jennifer Massa, ScD<sup>5</sup>,

Michelle D. Holmes, MD, DrPH<sup>1,4</sup>, Karin B. Michels, PhD<sup>1,4,6</sup>, Rulla M. Tamimi, ScD<sup>1,4</sup>, John P. Forman, MD<sup>7</sup>, Eva

S. Schernhammer, MD, DrPH<sup>1,4,8</sup>

<sup>1</sup> Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard

Medical School, 181 Longwood Avenue, Boston, Massachusetts 02115

<sup>2</sup> Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115

<sup>3</sup> Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, 615 North Wolfe

Street, Baltimore, Maryland 21205

<sup>4</sup> Department of Epidemiology, Harvard School of Public Heath, 677 Huntington Avenue, Boston, Massachusetts

02115

<sup>5</sup> Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115

<sup>6</sup> Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics, Gynecology and Reproductive

Biology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts

02115

<sup>7</sup>Renal Division, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115

<sup>8</sup> Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna), Bernardgasse 24/2.

A-1070 Vienna, Austria

Corresponding author: Elizabeth E. Devore, 181 Longwood Avenue, Room 448, Boston, Massachusetts, 02115;

phone: 617-525-2042; fax: 617-525-2008; email: nheed@channing.harvard.edu

Submitted to: Breast Cancer Research and Treatment

Online Resource 1. Relative risks of ER+ and ER- breast cancer over the follow-up period (1988-2012) in the Nurses' Health Study, according to current use of antihypertensive medication (n=94,233)

	ER+ tumors		ER- tumors		P-heterogeneity <sup>a</sup>
	Past/never use	Current use	Past/never use	Current use	
Any antihypertensive medication					
Cases/Person-years	2,962/1,147,784	1,791/615,414	569/1,150,060	311/616,851	
Age-adjusted RR (95% CI)	1.00 (ref)	1.08 (1.02 to 1.15)	1.00 (ref)	1.08 (0.94 to 1.25)	
Multivariable-adjusted RR (95% CI) <sup>b</sup>	1.00 (ref)	1.00 (0.94 to 1.07)	1.00 (ref)	1.02 (0.88 to 1.19)	1.0
Diuretics					
Cases/Person-years	3,976/1,496,152	776/266,897	738/1,499,226	142/267,535	
Age-adjusted RR (95% CI)	1.00 (ref)	1.07 (0.99 to 1.16)	1.00 (ref)	1.16 (0.96 to 1.39)	
Multivariable-adjusted RR (95% CI) <sup>b</sup>	1.00 (ref)	1.00 (0.92 to 1.08)	1.00 (ref)	1.11 (0.92 to 1.34)	0.6
Beta blockers		,			
Cases/Person-years	4,064/1,526,609	688/236,440	784/1,529,755	96/237,006	
Age-adjusted RR	1.00 (ref)	1.06	1.00 (ref)	0.81	
(95% CI)	, ,	(0.97 to 1.15)	, , ,	(0.65 to 1.00)	
Multivariable-adjusted RR (95% CI) <sup>b</sup>	1.00 (ref)	1.00 (0.92 to 1.09)	1.00 (ref)	0.77 (0.62 to 0.96)	0.02
Calcium channel blockers					
Cases/Person-years	4,300/1,619,742	452/143,306	786/1,623,104	94/143,657	
Age-adjusted RR (95% CI)	1.00 (ref)	1.13 (1.02 to 1.24)	1.00 (ref)	1.41 (1.13 to 1.75)	
Multivariable-adjusted RR (95% CI) b	1.00 (ref)	1.08 (0.98 to 1.20)	1.00 (ref)	1.36 (1.09 to 1.70)	0.1
ACE inhibitors				` '	
Cases/Person-years	4,379/1,624,767	374/138,432	814/1,628,176	66/138,735	
Age-adjusted RR (95% CI)	1.00 (ref)	0.94 (0.84 to 1.04)	1.00 (ref)	0.98 (0.76 to 1.27)	
Multivariable-adjusted RR (95% CI) <sup>b</sup>	1.00 (ref)	0.90 (0.81 to 1.00)	1.00 (ref)	0.95 (0.73 to 1.23)	0.8

<sup>&</sup>lt;sup>a</sup> P-heterogeneity calculated using the likelihood ratio test.

b These models are adjusted for age and body-mass index (<20, 20-21.9, 22-24.9, 25-29.9, ≥30 kg/m²), height (inches), oral contraceptive use (never, ever), menopausal status (premenopausal, postmenopausal), age at menopause (<45, 45-49, 50-52, ≥53 years), postmenopausal hormone use (among postmenopausal women only: never, past, current), parity and age at first birth (nulliparous, 1-2 children and <25 years old, 1-2 children and 25-29 years old, 1-2 children and ≥30 years old, ≥3 children and ≥25 years old), age at menarche (<12, 12, 13, ≥14 years old), family history of breast cancer (yes, no), history of benign breast disease (yes, no), alcohol intake (none, 1-7.49, 7.5-14.99, 15-29.9, ≥30 grams/day), physical activity level (quintiles of METhours/week), smoking status (never or past, current and <25 cigarettes/day, current and ≥25 cigarettes/day), and shift work history (none, 1-9, ≥10 years).